Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies

International Journal of Gynecological Cancer

Volumn 16, Issue 1, 2006, Pages 240-252

  Melichar, B ^a   Solichova D ^a   Freedman, R S ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cervical carcinoma; Endometrial carcinoma; Epithelial ovarian carcinoma; Immunotherapy; Neopterin

Indexed keywords

BIOCHEMICAL MARKER; CYTOKINE; ERYTHROPOIETIN; FERRITIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; INTERLEUKIN 2; IRON; NEOPTERIN; TRYPTOPHAN; ZINC;

ANEMIA; ASCITES FLUID; ASCITES TUMOR; BENIGN TUMOR; BIOLOGICAL ACTIVITY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; CHRONIC DISEASE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; GYNECOLOGIC CANCER; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MACROPHAGE; MACROPHAGE ACTIVATION; MALIGNANT NEOPLASTIC DISEASE; MICROENVIRONMENT; OVARY CARCINOMA; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEIN URINE LEVEL; REVIEW; TUMOR LOCALIZATION; UTERINE CERVIX CARCINOMA; UTERUS SARCOMA; VULVA CARCINOMA; ZINC METABOLISM; ZINC URINE LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOTHERAPY; MIDDLE AGED; NEOPLASM STAGING; NEOPTERIN; OVARIAN NEOPLASMS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 33645337897     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00294.x     Document Type: Review

References (134)

1. Loercher AE Nash MA Kavanagh JJ Platsoucas CD Freedman RS. Identification of an IL-10 producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 1999 163 6251 60.
2. Kooi S Zhang HZ Patenia R et al. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell Immunol 1996 174 116 28.
3. Melichar B Savary C Kudelka AP et al. Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin Cancer Res 1998 4 799 809.
4. Melichar B Nash MA Lenzi R Platsoucas CD Freedman RS. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumor infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin Exp Immunol 2000 119 19 27.
5. Abuzakouk M Feighery C O'Farrelly C. Collagenase and dispase enzymes disrupt lymphocyte surface molecules. J Immunol Methods 1996 194 211 6.
6. Moldawer LL Rogy MA Lowry SF. The role of cytokines in cancer cachexia. J Parenter Enteral Nutr 1992 16 43S 9S.
7. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982 389 39 48.
8. Gabay C Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999 340 448 53.
9. Wachter H Fuchs D Hausen A Reibnegger G Werner ER. Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 1989 27 81 141.
10. Zitko M Andrysek O Cernovska I Vasickova M. Renal excretion of neopterin and biopterin in patients with malignant melanoma and Hodgkin's disease. Neoplasma 1986 33 387 91.
11. Ogiwara S Hidaka H Sugimoto T et al. Elevated levels of oncopterin, N2-(3-aminopropyl)biopterin, a new pterin compound, in urine from patients with solid and blood cancers. J Biochem 1993 113 1 3.
12. Sakurai A Goto M. Neopterin: isolation from human urine. J Biochem 1967 61 142 5.
13. Wachter H Hausen A Grassmayr K. Erhöhte Ausscheidung von Neopterin im Harn von Patienten mit malignen Tumoren und mit Viruserkrankungen. Hoppe Seylers Z Physiol Chem 1979 360 1957 60.
14. Huber C Batchelor JR Fuchs D et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984 160 310 6.
15. Schoedon G Troppmair J Adolf G Huber C Niederwieser A. Interferon-gamma enhances biosynthesis of pterins in peripheral blood mononuclear cells by induction of GTP-cyclohydrolase I activity. J Interferon Res 1986 6 697 703.
16. Werner ER Werner-Felmayer G Fuchs D et al. Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1, and T24 cell. J Biol Chem 1990 265 3189 92.
17. Leitner KL Meyer M Leimbacher W et al. Low tetrahydrobiopterin biosynthetic capacity of human monocytes is caused by exon skipping in 6-pyruvoyl tetrahydropterin synthase. Biochem J 2003 373 681 8.
18. Fuchs D Milstien S Kramer A et al. Urinary neopterin concentrations vs total neopterin for clinical utility. Clin Chem 1989 35 2305 7.
19. Andert SE Greismacher A Zuckermann A Muller MM. Neopterin release from human endothelial cells is triggered by interferon-gamma. Clin Exp Immunol 1992 88 555 8.
20. Hofmann B Bass H Nishanian P et al. Different lymphoid cell populations produce varied levels of neopterin, beta2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumor necrosis factor-alpha. Clin Exp Immunol 1992 88 548 54.
21. Mountabarrik A Takahara S Nakanishi I et al. Interferon-gamma stimulates neopterin release from cultured kidney epithelial cells. Scand J Immunol 1994 39 27 30.
22. Troppmair J Nachbaur K Herold M et al. In-vitro and in-vivo studies on the induction of neopterin biosynthesis by cytokines, alloantigens and lipopolysaccharide (LPS). Clin Exp Immunol 1988 74 392 7.
23. Melichar B Touskova M Solichova D Kralickova P Kopecky O. CD4+ T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours. Scand J Clin Lab Invest 2001 61 363 70.
24. Melichar B Touskova M Tosner J Kopecky O. The phenotype of ascitic fluid lymphocytes in patients with ovarian carcinoma and other primaries. Onkologie 2001 24 156 60.
25. Williams JG Jurkovich GJ Maier RV. Interferon-gamma: a key immunoregulatory lymphokine. J Surg Res 1993 54 79 93.
26. Fuchs D Hausen A Reibnegger G et al. Neopterin as a marker for activated cell mediated immunity: application in HIV infection. Immunol Today 1988 9 150 5.
27. Werner-Felmayer G Werner ER Fuchs D et al. Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment. Cancer Res 1990 90 2863 7.
28. Bitterlich G Szabo G Werner ER et al. Selective induction of mononuclear phagocytes to produce neopterin by interferons. Immunobiology 1988 176 228 35.
29. Reibnegger G Aichberger C Fuchs D et al. Posttransplant neopterin excretion in renal allograft recipients - a reliable diagnostic aid for acute rejection and a predictive marker of long-term graft survival. Transplantation 1991 52 58 63.
30. Melichar B Gregor J Solichova D et al. Increased urinary neopterin in acute myocardial infarction. Clin Chem 1994 40 338 9.
31. Fuith LC Fuchs D Hausen A et al. Neopterin, a marker of cell-mediated immune activation in human pregnancy. Int J Fertil 1991 36 372 5.
32. Weiss G Kronberger P Conrad F et al. Neopterin and prognosis in patients with adenocarcinoma of the colon. Cancer Res 1993 53 260 5.
33. Marth C Weger E Muller-Holzner E et al. The prognostic value of nuclear roundness and neopterin in ovarian cancer. Eur J Cancer 1993 29A 1863 8.
34. Reibnegger G Bichler AH Dapunt O et al. Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix. Cancer Res 1986 46 950 5.
35. Yoshida N Ikemoto S Narita K et al. Serum neopterin levels in renal cell carcinoma. Pteridines 2000 11 133 6.
36. Thiounn N Pages F Flam T et al. IL-6 is a survival prognostic factor in renal cell carcinoma. Immunol Lett 1997 58 121 4.
37. Murr C Berant A Widschwendter M et al. Neopterin is an independent prognostic variable in females with breast cancer. Clin Chem 1999 45 1998 2004.
38. Hausen A Fuchs D Grunewald K et al. Urinary neopterin as marker for haematological neoplasias. Clin Chim Acta 1981 117 297 305.
39. Piccinini L Zironi S Federico M Pini LA Luppi G. Urinary neopterin in malignant lymphoma. Int J Biol Markers 1991 6 231 6.
40. Melichar B Jandik P Solichova D et al. Urinary neopterin excretion in colorectal cancer. Onkologie 1994 17 434 6.
41. Weiss G Fuchs D Hausen A et al. Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett 1993 321 89 92.
42. Murr C Fuchs D Gossler W et al. Enhancement of hydrogen peroxide-induced luminol-dependent chemiluminescence by neopterin depends on the presence of iron chelator complexes. FEBS Lett 1994 338 223 6.
43. Kojima S Icho T Kajiwara Y Kubota K. Neopterin as an endogenous antioxidant. FEBS Lett 1992 304 163 6.
44. Kojima S Nomura T Icho T et al. Inhibitory effect of neopterin on NADPH-dependent superoxide-generating oxidase of rat peritoneal macrophages. FEBS Lett 1993 329 125 8.
45. Kojima S Icho T Hayashi M et al. Inhibitory effects of 5,6,7,8-tetrahydroneopterin on adriamycin-induced cardiotoxicity. J Pharmacol Exp Ther 1993 266 1699 704.
46. Cerutti PA Trump BF. Inflammation and oxidative stress in carcinogenesis. Cancer Cells 1991 3 1 7.
47. Dreher D Junod AF. Role of oxygen free radicals in cancer development. Eur J Cancer 1996 32A 30 8.
48. Baier-Bitterlich G Fuchs D Murr C et al. Effect of neopterin and 7, 8-dihydroneopterin on tumor necrosis factor-a induced programmed cell death. FEBS Lett 1995 364 234 8.
49. Schobersberger W Hoffmann G Hobisch-Hagen P et al. Neopterin and 7,8-dihydroneopterin induce apoptosis in the rat alveolar epithelial cell line L2. FEBS Lett 1996 397 263 8.
50. Uberall F Werner-Felmayer G Schubert C et al. Neopterin derivatives together with cyclic guanosine monophosphate induce c-fos gene expression. FEBS Lett 1994 352 11 4.
51. Icho T Kojima S Shinohara N et al. Protective effects of tetrahydroneopterin against free radical-induced injury. Biochem Pharmacol 1993 45 1953 8.
52. Stuehr DJ Marletta MA. Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines or interferon-gamma. J Immunol 1987 139 518 25.
53. Werner-Felmayer G Werner ER Fuchs D et al. Tetrahydrobiopterin-dependent formation of nitrite and nitrate in murine fibroblasts. J Exp Med 1990 172 1599 607.
54. Albina JE. On the expression of nitric oxide synthase by human macrophages. Why no NO? J Leukoc Biol 1995 58 643 9.
55. Thomsen LL Lawton FG Knowles RG et al. Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994 54 1352 4.
56. Weinberg JB Misukonis MA Shami PJ et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 1995 86 1184 95.
57. Stuehr DJ Nathan CF. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989 169 1543 55.
58. Hibbs JB Taintor RR Vavrin Z Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988 157 87 94.
59. Ochoa JB Udekwu AO Billiar TR et al. Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg 1991 214 621 6.
60. Melichar B Karlicek R Tichy M. Increased urinary nitrate excretion in inflammatory bowel disease. Eur J Clin Chem Clin Biochem 1994 32 3 4.
61. Ochoa JB Curti B Peitzman AB et al. Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes. J Natl Cancer Inst 1992 84 864 7.
62. Freedman RS Kudelka AP Kavanagh JJ et al. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin-2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinomatosis. Clin Cancer Res 2000 6 2268 78.
63. Melichar B Lenzi R Rosenblum M et al. Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12. J Immunother 2003 26 270 6.
64. Melichar B Hu W Patenia R et al. rINF-gamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition. J Transl Med 2003 1 5.
65. Melichar B Ferrandina G Verschraegen CF et al. Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. Clin Cancer Res 1998 4 3069 76.
66. Uyttenhove C Pilotte L Theate I et al. Evidence for a tumor immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003 9 1269 74.
67. Weiss G Murr C Zoller H et al. Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells. Clin Exp Immunol 1999 116 435 40.
68. Modolell M Corraliza IM Link F Soler G Eichman K. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur J Immunol 1995 25 1101 4.
69. Bichler A Fuchs D Hausen A et al. Urinary neopterin excretion in patients with genital cancer. Clin Biochem 1982 15 38 40.
70. Bichler A Fuchs D Hausen A et al. Measurement of urinary neopterin in normal pregnant and non-pregnant women and in women with benign and malignant genital tract neoplasms. Arch Gynecol 1983 233 121 30.
71. Hetzel H Bichler A Fuchs D et al. Significance of urinary neopterin in gynecological oncology: follow-up of patients with ovarian cancer. Cancer Detect Prev 1983 6 263 6.
72. Reibnegger G Hetzel H Fuchs D et al. Clinical significance of neopterin for prognosis and follow-up in ovarian cancer. Cancer Res 1987 47 4977 81.
73. Bartel U Rabe H Schulz-Pinkus M. Erste Erfahrungen mit Neopterinbestimmungen im Urin von Frauen mit Genital- und Mammatumoren. Zentrabl Gynakol 1987 109 1226 32.
74. Szarka G Pulay T Csomor S Tran-Phoung-Mai Schumann B. The significance of neopterin determination as a tumour marker in ovarian cancer. Acta Chir Hung 1988 29 359 64.
75. Avall Lundqvist E Nordstrom L Sjovall K Eneroth P. Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies. Eur J Gynaecol Oncol 1989 10 395 405.
76. Fuith LC Fuchs D Hausen A et al. Urinary neopterin excretion in patients with uterine sarcoma. Cancer 1990 65 1228 31.
77. Gadducci A Ferdeghini M Malagnino G et al. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer. Gynecol Oncol 1994 52 386 91.
78. Park IS Lee YS Kim JC Hwang SG. Serum neopterin levels in ovarian tumors. Int J Gynaecol Obstet 1995 51 229 34.
79. Zeimet AG Windschwendter M Uhl-Steidl M et al. High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer. Br J Cancer 1997 76 1646 51.
80. Strickler HD Escoffery C Rattray C et al. Cervical intraepithelial neoplasia is not associated with elevated serum neopterin levels. Cancer Epidemiol Biomarkers Prev 1995 4 295 8.
81. Melichar B Zeimet A Artner-Dworzak E et al. Association between increased urinary neopterin concentrations in women with gynaecological cancer. TumorDiagn Ther 1993 14 110 2.
82. Fuith LC Dapunt O Hetzel H Reibnegger G Wachter H. Second-look operation in women with ovarian cancer: I. Concentrations of neopterin in urine and CA125 in serum at second-look laparotomy. Their relationship with prognosis. TumorDiagn Ther 1990 11 147 51.
83. Knox SN Robinson JB Im DD Logan L Rosenheim NB. The use of paclitaxel and cisplatin in a patient with epithelial ovarian cancer and human immunodeficiency virus. Gynecol Oncol 2000 76 118 22.
84. Fishman DA Viscarello RR Cass I Schwartz PE. Effect of combination chemotherapy with cisplatin and cyclophosphamide on human immunodeficiency virus type-1 surrogate markers in a patient with advanced epithelial ovarian cancer. Gynecol Oncol 1995 57 105 8.
85. Fuchs D Chiodi F Albert J et al. Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. AIDS 1989 3 285 8.
86. Reibnegger G Fuchs D Zangerle R Wachter H. Increased neopterin concentration in saliva of patients with HIV-1 infection. Clin Chem 1990 36 1379 80.
87. Weiss G Glaser K Kronberger P et al. Distinct distributions of D-erythro-neopterin in arteries and veins and its recovery by an enterohepatic circulation. Biol Chem Hoppe Seyler 1992 373 289 94.
88. Hausen A Aichberger C Konigsrainer A et al. Biliary and urinary neopterin concentrations in monitoring liver-allograft recipients. Clin Chem 1993 39 45 7.
89. Melichar B Malirova E Bures J et al. Gastric juice neopterin in Helicobacter pylori infection. FEMS Immunol Med Microbiol 1995 10 335 8.
90. Propst T Propst A Herold M et al. Spontaneous bacterial peritonitis is associated with high levels of interleukin-6 and its secondary mediators in ascitic fluid. Eur J Clin Invest 1993 23 832 6.
91. Satz N Joller-Jemelka HI Grob PJ et al. Tumormarker und immunomodulatorische Substanzen im Aszites - Ihre Wertigkeit als Screening und Diagnoseparameter. Schweiz Med Wochenschr 1989 119 762 5.
92. Melichar B Freedman RS. Immunology of the peritoneal cavity: relevance for host-tumor relation. Int J Gynecol Cancer 2002 12 3 17.
93. Runyon BA Hoefs JC Morgan TR. Ascitic fluid in malignancy-related ascites. Hepatology 1988 8 1104 9.
94. Haeger M Swahn M Hahlin M Horvath G Bengtsson A. Increased concentrations of neopterin in plasma, ascites and ovarian cyst fluid in malignant tumours compared with benign ovarial tumours. Anticancer Res 1996 16 3189 92.
95. Melichar B Savary CA Patenia R et al. Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma. Int J Gynecol Cancer 2003 13 435 43.
96. Zeimet AG Widschwendter M Knabbe C et al. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol 1998 16 1861 8.
97. Landmann R Ludwig C Wesp M et al. Prolonged interferon-gamma application by subcutaneous infusion in cancer patients: differential response of serum CD14, neopterin, and monocyte HLA class I and II antigens. J Interferon Res 1992 12 103 11.
98. Urba WJ Kopp WC Clark JW et al. The in vivo immunomodulatory effects of recombinant interferon gamma plus recombinant tumor necrosis factor-alpha. J Clin Oncol 1991 9 1831 9.
99. Fuith LC Fuchs D Hausen A et al. Effects of interferon-alpha on macrophage activation in patients with ovarian carcinoma and cervical dysplasia. J Clin Lab Immunol 1989 29 65 9.
100. Melichar B Solichova D Jebavy L. Elevation de la neopterine apres traitement par le facteur stimulant des colonies granulo-macrophagiques (GM-CSF). Presse Med 1994 23 581.
101. Marth C Weiss G Koza A et al. Increased production of immune activation marker neopterin by colony-stimulating factors in gynecological cancer patients. Int J Cancer 1994 58 20 3.
102. Lissoni P Tisi E Brivio F et al. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2. Eur J Cancer 1991 27 1014 6.
103. Motzer RJ Rakhit A Thompson JA et al. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-a2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 2001 21 257 63.
104. Grabstein KH Urdal DL Tushinsky RJ et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986 232 506 8.
105. Marth C Mull R Gastl G et al. Die intraperitoneale Instillation von Interferon-gamma zur Behandlung des refraktaren Ovarialkarzinoms. Geburtshilfe Frauenheilkd 1989 49 987 91.
106. Balkwill F Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001 357 539 45.
107. Elgert KD Alleva DG Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 1998 64 275 90.
108. Alleva DG Burger CJ Elgert KD. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E. J Immunol 1994 153 1674 86.
109. Yacyshyn MBB Poppema S Berg A et al. CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy. Int J Cancer 1995 61 470 4.
110. Tancini G Barni S Rescaldani R et al. Analysis of T helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms. Oncology 1990 47 381 4.
111. Richner J Ambinder EP Hoffmann K Feuer EJ Bekesi G Number of helper T cells and phytohemagglutinin stimulation correlate in cancer patients. Cancer Immunol Immunother 1991 34 138 42.
112. Fuchs D Banekovich M Hausen A et al. Neopterin estimation compared with the ratio of T-cell subpopulations in persons infected with human immunodeficiency virus-1. Clin Chem 1988 34 2415 7.
113. Finkel TH Tudor-Williams G Banda NK et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1995 1 129 34.
114. Muro-Cacho CA Pantaleo G Fauci AS. Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J Immunol 1995 154 5555 66.
115. Uzzo RG Rayman P Kolenko V et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res 1999 5 1219 29.
116. Baier-Bitterlich G Fuchs D Wachter H. Chronic immune stimulation, oxidative stress, and apoptosis in HIV infection. Biochem Pharmacol 1997 53 755 63.
117. Wirleitner B Obermoser G Bock G et al. Induction of apoptosis in human blood T cells by 7,8-dihydroneopterin: the difference between healthy controls and patients with systemic lupus erythematosus. Clin Immunol 2003 107 152 9.
118. Hagen C Froland A Weberg E. Lymphocyte transformation in cancer patients. Lancet 1972 1 1340.
119. Garrioch DB Good RA Gatti RA. Lymphocyte response to PHA in patients with non-lymphoid tumours. Lancet 1970 1 618.
120. Lee WJ Chang KJ Lee CS Chen KM. Selective depression of T-lymphocyte subsets in gastric cancer patients: an implication of immunotherapy. J Surg Oncol 1994 55 165 9.
121. Levey DL Srivastava PK. Alterations in T cells of cancer-bearers: whence specificity? Immunol Today 1996 17 365 8.
122. Melichar B Jandik P Krejsek J et al. Mitogen-induced lymphocyte proliferation and systemic immune activation in cancer patients. Tumori 1996 82 218 20.
123. Melichar B Savary CA Kudelka AP et al. Dendritic cells in ascites associated with peritoneal carcinomatosis. Proc AACR 1997 38 35 6.
124. O'Doherty U Steinman RM Peng M et al. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium. J Exp Med 1993 178 1067 78.
125. Allen JI Bell E Boosalis MG et al. Association between urinary zinc excretion and lymphocyte dysfunction in patients with lung cancer. Am J Med 1985 79 209 15.
126. Voyatzoglou V Mountokalakis T Tsata-Voyatzoglou V Koutselenis A Skalkeas G. Serum zinc levels and urinary zinc excretion in patients with bronchogenic carcinoma. Effects of tumor resection. Am J Surg 1982 144 355 8.
127. Melichar B Malir F Jandik P et al. Increased urinary zinc excretion in cancer patients is linked to immune activation and renal tubular cell dysfunction. Biometals 1995 8 205 8.
128. Melichar B Jandik P Malir F et al. Association between renal tubular cell dysfunction and increased urinary zinc excretion in cancer patients. Scand J Clin Lab Invest 1994 55 149 52.
129. Price RG. The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol 1992 38 S14 9.
130. Fuchs D Hausen A Reibnegger G et al. Immune activation and the anaemia associated with chronic inflammatory disorders. Eur J Haematol 1991 46 65 70.
131. Means RT. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells 1995 13 32 7.
132. Weinberg ED. Iron withholding: a defence against infection and neoplasia. Physiol Rev 1984 64 65 102.
133. Hausen A Fuchs D Reibnegger G et al. Reduction of ferric iron by 7, 8-dihydroneopterin. Pteridines 1990 2 83 5.
134. Wachter H Artner-Dworzak E Fuchs D et al. Association between neopterin and iron metabolism in cancer patients. Tumor Diagn Ther 1990 11 229 32.